Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial

BACKGROUND: Patients with permanent atrial fibrillation have poor outcomes, exercise capacity, and quality of life even on optimal anticoagulation. Based on mechanistic and observational data, we tested whether the mineralocorticoid receptor antagonist spironolactone can improve exercise capacity, E...

Descripción completa

Detalles Bibliográficos
Autores principales: Shantsila, Eduard, Shahid, Farhan, Sun, Yongzhong, Deeks, Jonathan, Calvert, Melanie, Fisher, James P., Kirchhof, Paulus, Gill, Paramjit S., Lip, Gregory Y. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726985/
https://www.ncbi.nlm.nih.gov/pubmed/32909497
http://dx.doi.org/10.1161/JAHA.119.016239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726985/
https://www.ncbi.nlm.nih.gov/pubmed/32909497
http://dx.doi.org/10.1161/JAHA.119.016239

Ejemplares similares